These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 20946665)

  • 1. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
    Yau C; Esserman L; Moore DH; Waldman F; Sninsky J; Benz CC
    Breast Cancer Res; 2010; 12(5):R85. PubMed ID: 20946665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
    Yau C; Sninsky J; Kwok S; Wang A; Degnim A; Ingle JN; Gillett C; Tutt A; Waldman F; Moore D; Esserman L; Benz CC
    Breast Cancer Res; 2013; 15(5):R103. PubMed ID: 24172169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ; Moore DH; Tsing PJ; Chu PW; Yau C; Ozanne E; Chung RE; Tandon VJ; Park JW; Baehner FL; Kreps S; Tutt AN; Gillett CE; Benz CC
    Breast Cancer Res Treat; 2011 Sep; 129(2):607-16. PubMed ID: 21597921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
    Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
    PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
    Giorgi Rossi P; Lebeau A; Canelo-Aybar C; Saz-Parkinson Z; Quinn C; Langendam M; Mcgarrigle H; Warman S; Rigau D; Alonso-Coello P; Broeders M; Graewingholt A; Posso M; Duffy S; Schünemann HJ;
    Br J Cancer; 2021 Apr; 124(9):1503-1512. PubMed ID: 33597715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
    Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer.
    Liu Q; Wang Z; Kong X; Wang X; Qi Y; Gao R; Fang Y; Wang J
    DNA Cell Biol; 2020 Apr; 39(4):671-682. PubMed ID: 32040341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancers are increased in black women regardless of age or body mass index.
    Stead LA; Lash TL; Sobieraj JE; Chi DD; Westrup JL; Charlot M; Blanchard RA; Lee JC; King TC; Rosenberg CL
    Breast Cancer Res; 2009; 11(2):R18. PubMed ID: 19320967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
    Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
    PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
    Tutt A; Wang A; Rowland C; Gillett C; Lau K; Chew K; Dai H; Kwok S; Ryder K; Shu H; Springall R; Cane P; McCallie B; Kam-Morgan L; Anderson S; Buerger H; Gray J; Bennington J; Esserman L; Hastie T; Broder S; Sninsky J; Brandt B; Waldman F
    BMC Cancer; 2008 Nov; 8():339. PubMed ID: 19025599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.
    Cascione L; Gasparini P; Lovat F; Carasi S; Pulvirenti A; Ferro A; Alder H; He G; Vecchione A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2013; 8(2):e55910. PubMed ID: 23405235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
    Kwon MJ
    Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
    Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
    Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.